Compare Pfizer Inc (PFE) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Pfizer Inc trades at $24.92 (market cap $142.14B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.5. The key difference: Pfizer Inc pays a 6.9% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| PFE | VEA | |
|---|---|---|
Market Cap | $142.14B | — |
Volume | 29,869,932 | — |
Sector | Health | — |
52-Week High | $28.56 | $72.39 |
52-Week Low | $23.29 | $56.02 |
Enterprise Value | $192.80B | — |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
VEA trades at $69.23, down 0.67% today, with technical indicators showing a bearish trend. The ETF's moving averages signal selling pressure, while oscillators remain neutral. Recent news highlights strong 2026 performance against U.S. benchmarks and institutional buying interest. Vanguard's low 0.03% expense ratio and focus on developed ex-U.S. markets provide cost-efficient diversification.
Outlook is mixed: technical weakness contrasts with fundamental appeal via valuation discounts to U.S. stocks. Risks include developed market central bank tightening and political volatility. Analysts note long-term outperformance potential, but near-term sentiment is cautious amid bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
